Medical liquid composition for aerial administration
US-2024358636-A1 · Oct 31, 2024 · US
US10836836B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10836836-B2 |
| Application number | US-202016789598-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 13, 2020 |
| Priority date | Apr 5, 2016 |
| Publication date | Nov 17, 2020 |
| Grant date | Nov 17, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided are HPMCAS powder having high solubility when dissolved in a solvent and being capable of suppressing generation of undissolved materials; and a method for producing the powder. More specifically, provided is hypromellose acetate succinate powder having an average ratio of L to D of from 2.0 to 3.0, wherein L and D mean maximum and minimum diameters of each particle, respectively. Also provided is a method for producing a hypromellose acetate succinate, comprising the steps of: dissolving hypromellose powder in a solvent, esterifying the dissolved hypromellose with succinic anhydride and acetic anhydride in the presence of a catalyst to obtain a reaction mixture, and mixing the reaction mixture with water to precipitate hypromellose acetate succinate, wherein the reaction mixture just before being mixed with the water has a viscosity of from 100 to 200 Pa·s.
Opening claim text (preview).
That which is claimed is: 1. A method for producing a composition for solid dispersion, comprising the step of removing a solvent from a solution comprising the hypromellose acetate succinate powder having an average ratio of L to D of from 2.0 to 3.0, wherein L and D mean maximum and minimum diameters of each particle, respectively, a drug and the solvent. 2. The method according to claim 1 , wherein the hypromellose acetate succinate powder has a specific surface area of from 2.0 to 5.0 m 2 /g or more. 3. The method according to claim 1 , wherein the hypromellose acetate succinate powder has a loose bulk density of from 0.10 to 0.25 g/mL. 4. The method according to claim 1 , wherein the hypromellose acetate succinate powder comprises 10% by weight or less of component not soluble at 20° C. in such a weight of acetone as to be 10 times the weight of the powder.
Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose · CPC title
Cellulose; Derivatives thereof · CPC title
Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title
Preparation of cellulose ether-esters · CPC title
Processes · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.